Trademark Overview
On Wednesday, July 12, 2023, a trademark application was filed for MULTABODY with the United States Patent and Trademark Office. The USPTO has given the MULTABODY trademark a serial number of 98081053. The federal status of this trademark filing is RESPONSE AFTER NON-FINAL ACTION - ENTERED as of Tuesday, October 22, 2024. This trademark is owned by Radiant Biotherapeutics. The MULTABODY trademark is filed in the Chemical Products, Pharmaceutical Products, Computer & Software Services & Scientific Services, Personal, and Legal & Social Services categories with the following description:
Pharmaceutical and veterinary preparations, namely, pharmaceutical preparations based on antibodies, bi and multispecific antibodies as well as fragments, including monovalent antibodies, derivatives or conjugates of any of these for use with regard to the treatment of cancer, infectious, immune, autoimmune, inflammatory, neurodegenerative and cardiovascular diseases; pharmaceutical preparations based on human monoclonal antibodies for the treatment of cancer, AIDS (acquired immune deficiency syndrome) and other infectious diseases, immune and autoimmune diseases, inflammatory diseases and cardiovascular diseases
Chemical, biochemical, biological, and biotechnological, preparations, namely, antibodies, bi- and multispecific antibodies as well as fragments, monovalent antibodies, derivatives of conjugates of any of these for in vitro and in vivo scientific and industrial research and development with regard to diseases; biochemicals, namely, monoclonal antibodies for in vivo or in vitro scientific research and development regarding cancer, AIDS (acquired immune deficiency syndrome), and other infectious diseases, immune and autoimmune diseases, inflammatory diseases and cardiovascular diseases
Licensing of intellectual property in the field of medicine
Medical, scientific and biological research; research in antibodies, bi and multispecific antibodies or fragments, monovalent antibodies, derivatives or conjugates of any of these and development services of new pharmaceutical products based on antibodies, bi and multispecific antibodies or fragments, monovalent antibodies, derivatives or conjugates of any of these; chemical analysis; development of pharmaceutical preparations and medicines containing antibodies, bi- and multispecific antibodies or fragments, monovalent antibodies, derivatives or conjugates of any of these; medical and scientific research, namely, biological scientific research into human monoclonal antibodies and development of pharmaceutical products based on human monoclonal antibodies for the treatment of cancer, AIDS (acquired immune deficiency syndrome) and other infectious diseases, immune and autoimmune diseases, inflammatory diseases and cardiovascular diseases
